Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated other comprehensive income (loss)
Balance at Dec. 31, 2021 $ 9,181,203 $ 758 $ 37,618,438 $ (28,437,993)  
Balance, Shares at Dec. 31, 2021   7,584,980      
Issuance of common shares upon exercise of stock options 47,700 $ 3 47,697    
Issuance of common shares upon exercise of stock options, Shares   26,500      
Issuance of common shares upon exercise of warrants 110,000 $ 6 109,994    
Issuance of common shares upon exercise of warrants, Shares   61,111      
Issuance of common shares in connection with Equity Financing 2,373,561 $ 27 2,373,534    
Issuance of common shares in connection with Equity Financing, Shares   263,729      
Stock-based compensation expense 713,330   713,330    
Modification of warrant in equity     450,478    
Deemed dividend on modification of warrant     (450,478)    
Foreign currency translation adjustment 1,721       $ 1,721
Net loss (3,413,845)     (3,413,845)  
Balance at Mar. 31, 2022 9,013,670 $ 794 40,862,993 (31,851,838) 1,721
Balance, Shares at Mar. 31, 2022   7,936,320      
Balance at Dec. 31, 2022 8,507,793 $ 1,096 52,729,942 (44,207,272) (15,973)
Balance, Shares at Dec. 31, 2022   10,955,904      
Issuance of restricted stock 164,070 $ 4 164,066    
Issuance of restricted stock, Shares   40,500      
Stock-based compensation expense 537,522   537,522    
Foreign currency translation adjustment (9,301)       (9,301)
Net loss (4,116,876)     (4,116,876)  
Balance at Mar. 31, 2023 $ 5,083,208 $ 1,100 $ 53,431,530 $ (48,324,148) $ (25,274)
Balance, Shares at Mar. 31, 2023   10,996,404